The Centers for Disease Control and Prevention recently released guidelines for a new regimen that greatly reduces the duration of treatment and number of doses for latent tuberculosis infection (LTBI)—a prolonged asymptomatic infection that can progress to active TB. This new regimen, called the 12-dose regimen, consists of 12 once-weekly doses of isoniazid (INH) and rifapentine (RPT) under directly observed therapy (DOT). It is considered one of the biggest breakthroughs in the treatment of LTBI since the 1960s.

**Status of TB Nationally and Locally**

More than 11 million people in the United States have LTBI, and about 5%-10% (550,000 to 1.1 million) of them will develop active TB if not treated. While TB cases in the United States have been declining since 1993, TB remains prevalent worldwide. One-third of the world’s population is infected, and each year nearly 9 million people around the world become sick with active TB. In Los Angeles County alone, there were 673 active cases of TB in 2010. As shown in Figure 1, the active TB case rate for 2010 in Los Angeles County was nearly twice the national average.

**New Tool for Treating LTBI**

The 12-dose regimen reduces treatment from 270 daily doses over nine months to 12 once-weekly doses given over three months. The 12-dose regimen was recommended after a large randomized control trial found a combination of INH and RPT administered in 12 once-weekly doses with DOT was as effective in preventing TB as the 270-dose INH regimen, which is usually self-administered by patients daily over nine months. The 12-dose regimen also had greater rates of completion than the U.S. standard 270-dose INH regimen.

The administration of this new regimen should be provided under DOT by specially trained DOT workers to ensure the completion of all doses. Patients also need to undergo monthly clinical monitoring that includes inquiries about side effects and a physical assessment for signs of adverse events.

*continued on page 2*
Key Points Regarding the 12-Dose Regimen for Treatment of LTBI

- The 12-dose regimen is recommended as an equal option for treating LTBI in otherwise healthy people, aged 12 years and older, who have any one of the following:
  - Recent contact with someone who has TB
  - Tested positive for TB infection from an Interferon Gamma Release Assays-serum screening or through a tuberculin skin test conversion
  - Radiographic findings of healed pulmonary TB
  - HIV-infected, who are otherwise healthy, and NOT taking antiretroviral medicines.
- The 12-dose regimen can be considered for other groups when it offers practical advantages, such as completion within a limited time frame.
- The 12-dose regimen is NOT recommended for the following:
  - Children younger than 2 years of age
  - People with HIV/AIDS who are taking antiretroviral medicines
  - Pregnant women or women who expect to become pregnant during treatment
  - People who are presumed to have been infected with isoniazid-resistant or rifampin-resistant M. tuberculosis.
- Evidence for broader usage of the 12-dose regimen is currently being gathered.
- DOT is recommended for the 12-dose regimen. Additional studies on self-administration of the 12-dose regimen are underway.
- Treatment of latent TB infection should be initiated after the possibility of TB disease has been excluded.

The 12-dose regimen does not replace existing treatment options for latent TB infection but is another option for treatment with certain patient populations (see Key Points box). The current primary and secondary CDC recommended regimens are still Isoniazid (daily) for 6-9 months or Rifampin (daily) for 4 months, and they do not require DOT protocols.

Moving Forward Toward TB Elimination
Treating LTBI so it does not progress to active TB is a cornerstone of the U.S. strategy for TB elimination. An estimated 300,000 to 400,000 people begin treatment for LTBI each year; however, 40% do not complete the lengthy treatment. Public health officials hope the 12-dose regimen will improve patient adherence.

The three core strategies for eliminating TB within the United States are as follows: 1) Early identification, treatment and isolation of active TB cases; 2) Timely identification, evaluation and treatment of exposed contacts; and 3) Targeted testing and treatment of high-risk persons with LTBI.

All three strategies require partnerships between public health and clinicians. The LA County Department of Public Health focuses on the first two priorities. For the third priority, primary care providers are essential, as they play a crucial role in screening, evaluating, and treating high-risk persons. As an essential primary care service, Medi-Cal and most major medical insurance plans now cover the FDA-approved IGRA (Interferon Gamma Release Assays-serum) screening methods (e.g., Quantiferon, T-Spot), the more specific TB infection tests, as well as INH therapy.

With this 12-dose regimen, primary care providers now have a new option for treatment to strengthen their efforts. Medi-Cal will now reimburse the treatment costs for the new 12-dose regimen, including medications and DOT service.

All patients receiving the 12-dose regimen must receive it as DOT, including monthly clinical monitoring to assess any adverse events and potential side effects. Providers should contact the LA County TB Control Program for any consultative support on LTBI treatment, at (213) 744-6160. Currently, the Department of Public Health is examining the feasibility of using the 12-dose regimen in its high-risk and other clinic settings.

Further, although INH is FDA-approved as preventive therapy for TB infection, approval for the use of rifapentine in TB infection treatment is pending (as of December 9, 2011), and its approval is not expected until 2013. Therefore, if providers use the 12-dose regimen, they will be utilizing rifapentine off-label.

Importance of Treating LTBI
Although the initial cost of the new 12-dose regimen will be higher, the long-term personal and public health benefits can be substantial. Since more patients are expected to complete treatment, a reduction in progression of LTBI to active TB is expected. This will help eliminate the cost of treating future potential TB cases and reduce the associated morbidity, plus decrease the spread of active TB disease in our community.

For the most updated information on the treatment options for TB infection and other TB-related issues, visit www.publichealth.lacounty.gov/tb.

Frank Alvarez, MD, MPH, is director, and Jenna Kirschenman, MPH, MSW, is public health associate, Tuberculosis Control Program, Los Angeles County Department of Public Health.

REFERENCES
Latest Mortality Report Shows Leading Causes of Death on the Decline

In 2008, the age-adjusted death rate in Los Angeles County was 601 deaths per 100,000 population, which was dramatically lower than the United States rate of 759 deaths per 100,000 population, according to “Mortality in Los Angeles County, 2008: Leading causes of death and premature death with trends for 1999-2008,” a December 2011 report from the LA County Department of Public Health.

Continuing a more than 20-year trend in declining death rates in the county, from 1999 to 2008, the overall death rate in the county decreased 25%. During this time, there was a 42% decrease in the death rate from coronary heart disease, a 44% decrease from stroke, and a 28% decrease from lung cancer.

The report also showed that injuries (homicides, motor vehicle crashes, suicide, and alcohol) are leading causes of premature deaths among both males and females. (Premature death is defined as death before the age of 75, a standard cut-off used in public health.)

Data highlights for 2008 (rates are age-adjusted)

- In 2008, there were 58,043 deaths, a 0.5% decrease from 2007. The death rate was 601 deaths per 100,000 population, a 4% decrease from 2007.
- On an average day in LA County, 159 people died, including 37 from coronary heart disease, 37 from cancer, 10 from injuries (homicide, suicide, and unintentional), and 9 from stroke. Five deaths were among children and young adults less than 25 years.

- Twenty-three of every 100 deaths were caused by cancer (13,425 deaths). Among those who died of cancer, lung cancer was the most common (2,910 deaths), followed by colorectal cancer (1,365 deaths), and breast cancer (1,079 deaths).
- Death rates were higher for men than women for every leading cause of death and premature death, except Alzheimer’s disease and breast cancer.

Data highlights for 1999-2008 (rates are age-adjusted)

- During the last 10 years, the overall death rate decreased 25%, from 798 to 601 deaths per 100,000 population.
- Coronary heart disease, injury, and motor vehicle crashes have been the three leading causes of premature death since 1999.
- Since 1999, the number of deaths from Alzheimer’s disease has nearly tripled from 772 in 1999 to 2,121 in 2008.
- Diabetes became the fifth-leading cause of death in 2008 after nine years as the sixth-leading cause.

For a printed copy of the report, call (213) 240-7785. Or view the report online at www.publichealth.lacounty.gov/dca/dcreportspubs.htm.

46th Annual Meeting of the California Tuberculosis Controllers Association

The Cutting Edge of TB Control: New Challenges and New Solutions

Local and national conference speakers will focus on recent developments in the diagnosis and treatment of tuberculosis:

- CDC Study 26 – New Short Course Therapy for LTBI Treatment Using INH and Rifapentine. Speaker: Carol Dukes Hamilton, MD
- Cost-Effectiveness of LTBI Treatment. Speaker: David Holland, MD
- Epidemiology of TB in California. Speaker: Jennifer Flood, MD
- Laboratory Advances and Challenges. Speaker: Ed Desmond, PhD
- Enhanced Focus on HIV/AIDS Screening in the TB Patient Population

California Endowment/Center for Healthy Communities
1000 N. Alameda St., Los Angeles, CA 90012

Advanced registration required. Register at www.ctca.org

For additional information, contact
Robert Miodovski, MPH, Senior Health Educator, at (213) 744-6229

SAVE THE DATE
Tuesday, May 15, 2012
Achieving and Maintaining Asthma Control

Marilyn Li, MD
Janet Scully, MPH

Although asthma occurs in persons of all ages, the highest prevalence of active asthma occurs in children and youth. In Los Angeles County, the prevalence of active childhood asthma is 9.0% while the lifetime prevalence of asthma in children younger than 18 years is 13.8%. Asthma impacts the quality of life of patients, their families, and society, including the cost of routine and urgent medical care, missed school or work days, missed opportunities for participating in activities that may trigger asthma, the expense and adverse effects of medications, and the mortality associated with the disease.

The National Asthma Education and Prevention Program (NAEPP) has developed “Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma—Full Report 2007” (EPR-3). To reduce the burden of asthma, this resource provides detailed asthma recommendations for three age groups: 0-4 years, 5-11 years, and 12 years and older.

Definition and Diagnosis

Asthma is characterized by airway inflammation, airway hyper-responsiveness, and episodic reversible airway obstruction. To establish the diagnosis of asthma, the recommended methods include a detailed medical history, physical examination, spirometry for all patients 5 years of age.

Asthma Severity and Assessment of Asthma Control

Once the diagnosis of asthma is established, the next step is to assess asthma severity (which is defined by the intrinsic intensity of the disease process) to guide the initiation of asthma therapy. After the initial visit, the EPR-3 focuses on monitoring asthma control, defined by the degree to which the manifestations of asthma are minimized by therapeutic interventions, and the goals of asthma therapy are met.

When assessing asthma severity or control, the EPR-3 defines the two key domains of impairment and risk. Impairment is defined by the frequency and intensity of asthma symptoms that the patient is experiencing, and functional limitations, if any. Risk is the likelihood of asthma exacerbations, decline in lung function or poor lung growth, or risk of adverse effects from the medication.

At the baseline visit, the EPR-3 provides clear stepwise guidelines for the different age groups for the initiation of therapy. (See Table 1 for youth ≥12 years.) For the 0-4 age group, consider daily long-term controller therapy in children who have a positive Asthma Predictive Index (API), a clinical index based on the presence of wheezing before 3 years of age. The presence of one major risk factor (personal history of atopic dermatitis, or parent history of asthma) or two minor risk factors (allergic rhinitis, eosinophilia >4%, or wheezing apart from colds) is predictive of the presence of asthma after the age of 6 years.

For the age groups 5-11 and 12 years and above, involve the patient in developing a written asthma action plan, promote physical activity, and provide education at the appropriate literacy level about asthma triggers and environmental avoidance measures.

At the follow-up visit and all subsequent visits, monitor asthma control by assessing impairment and risk and adjusting asthma therapy by using the stepwise approach (Table 2).

Goals of Asthma Therapy

The goals of asthma therapy are to achieve and maintain asthma control by reducing both impairment and risk. By reducing impairment, the goal is to prevent chronic and troublesome symptoms, require infrequent use (2 days per week or less) of inhaled short-acting beta₂-agonists, maintain normal (or near normal) lung function, maintain normal activity levels (including exercise), and meet the patient and their family’s expectations of and satisfaction with asthma care. By reducing risk, the goal is to prevent recurrent exacerbations of asthma (including reducing the need for urgent or emergent asthma care), prevent the loss of lung function, and provide optimal pharmacotherapy with minimal or no adverse effects.

To achieve asthma control, there are four identified components of care: assessing and monitoring asthma (Table 3), patient education, including self-monitoring and a written asthma action plan; control of environmental factors and comorbid conditions; and a tailored medication treatment plan.

The general principles for all age groups are to incorporate the four components of care, initiate appropriate asthma therapy based on the asthma severity at the initial visit, and then step up or step down asthma therapy based on asthma control at all subsequent visits. The guidelines have also included information on usual doses for long-term controller therapy and estimated comparative daily dosages for inhaled steroids.

Conclusion

A systematic guidelines-based approach to the treatment of asthma, especially in an inner-city setting, has been shown to improve asthma control significantly. The entire EPR-3 document is available at www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.

Consider referral to an asthma specialist if signs and symptoms are atypical, if there is no improvement on therapy, if there are problems with a differential diagnosis, or if additional testing is indicated. Los Angeles County resources can be accessed through the following website, www.asthmacoalitionla.org.
Table 1. Components and Classification of Asthma Severity in Children 12 Years of Age and Older – Not Currently Taking Controllers

<table>
<thead>
<tr>
<th>Components of Severity</th>
<th>Classification of Asthma Severity ≥ 12 Years of Age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intermittent</td>
</tr>
<tr>
<td></td>
<td>Persistent</td>
</tr>
<tr>
<td></td>
<td>Mild</td>
</tr>
<tr>
<td>Impairment</td>
<td></td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>≤2 days/week but not daily</td>
</tr>
<tr>
<td>Normal FEV₁/FVC:</td>
<td>8-19 yr 85%</td>
</tr>
<tr>
<td>Symptom control</td>
<td>≤2x/month</td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>≤2 days/week but not daily</td>
</tr>
<tr>
<td>Interference with normal activity</td>
<td>None</td>
</tr>
<tr>
<td>Lung function</td>
<td>Normal FEV₁ between exacerbations</td>
</tr>
<tr>
<td>Exacerbations</td>
<td>0-1/year</td>
</tr>
<tr>
<td>Risk</td>
<td>Consider severity and interval since last exacerbation</td>
</tr>
<tr>
<td>Recommended Step</td>
<td>Step 1</td>
</tr>
<tr>
<td>for Initiating Treatment</td>
<td>See Table 3 for steps</td>
</tr>
<tr>
<td>In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly</td>
<td></td>
</tr>
</tbody>
</table>

Source: Adapted from NAEPP EPR-3. Public domain document.

To view Asthma Classification tables for children aged 0-4 and 5-11, visit the National Heart Lung and Blood Institute website at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
Table 2. Assessing Asthma Control in Youth ≥12 Years of Age and Adults

<table>
<thead>
<tr>
<th>Components of Control</th>
<th>Classification of Asthma Control (Youth ≥12 Years of Age and Adults)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Well Controlled</td>
</tr>
<tr>
<td><strong>Impairment</strong></td>
<td></td>
</tr>
<tr>
<td>Symptoms</td>
<td>≤2 days/week</td>
</tr>
<tr>
<td>Nighttime awakenings</td>
<td>1x/month</td>
</tr>
<tr>
<td>Interference with</td>
<td>None</td>
</tr>
<tr>
<td>normal activity</td>
<td></td>
</tr>
<tr>
<td>Short-acting beta,,-agonist use for symptom control (not prevention of EIB)</td>
<td>≤2 days/week</td>
</tr>
<tr>
<td>FEV, or peak flow</td>
<td>&gt;80% predicted/personal best</td>
</tr>
<tr>
<td>Validated Questionnaires</td>
<td></td>
</tr>
<tr>
<td>ATAQ</td>
<td>0</td>
</tr>
<tr>
<td>ACQ</td>
<td>≤0.75</td>
</tr>
<tr>
<td>ACT</td>
<td>≥20</td>
</tr>
<tr>
<td><strong>Risk</strong></td>
<td></td>
</tr>
<tr>
<td>Exacerbations</td>
<td>0-1/year</td>
</tr>
<tr>
<td>Consider severity and interval since last exacerbation</td>
<td></td>
</tr>
<tr>
<td>Progressive loss of lung function</td>
<td>Evaluation requires long-term follow-up care</td>
</tr>
<tr>
<td>Treatment-related adverse effects</td>
<td>Medication side effects can vary in intensity from none to very troublesome and worrisome. The level of intensity does not correlate to specific levels of control but should be considered in the overall assessment of risk.</td>
</tr>
</tbody>
</table>

Source: Adapted from NAEPP EPR-3. Public domain document.

To view the Asthma Assessment tables for children ages 0-4 and 5-11, visit the National Heart Lung and Blood Institute website at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.
### Table 3. Stepwise Approach for Managing Asthma in Youths 12 Years and Older and Adults

<table>
<thead>
<tr>
<th>Intermittent Asthma</th>
<th>Persistent Asthma: Daily Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Consult with an asthma specialist if Step 4 care or higher is required. Consider consultant at Step 3.</td>
</tr>
</tbody>
</table>

#### Step 1
- **Preferred**
  - Low-dose ICS**
- **Alternative**
  - Cromolyn, LTRA†, Nedocromil, or Theophylline

#### Step 2
- **Preferred**
  - Low-dose ICS + LABA‡
  - OR
  - Medium-dose ICS
- **Alternative**
  - Low-dose ICS + either LTRA, Theophylline, or Zileuton

#### Step 3
- **Preferred**
  - Medium-dose ICS + LABA
  - OR
  - Medium-dose ICS + either LTRA, Theophylline, or Zileuton

#### Step 4
- **Preferred**
  - High-dose ICS + LABA + oral corticosteroid
  - AND
  - Consider Omalizumab for patients who have allergies

#### Step 5
- **Preferred**
  - High-dose ICS + LABA + oral corticosteroid
  - AND
  - Consider Omalizumab for patients who have allergies

#### Step 6
- **Preferred**
  - High-dose ICS + LABA + oral corticosteroid
  - AND
  - Consider Omalizumab for patients who have allergies

---

**Quick-Relief Medication for All Patients**

- **Step up if needed**
  - (First, check adherence, environmental control, and comorbid conditions)
- **Assess Control**
  - Step down if possible
  - (And asthma is controlled as least 3 months)

**Source:** Adapted from NAEPP EPR-3. Public domain document.

---

**To view the stepwise approach for Managing Asthma tables for children ages 0-4 and 5-11, visit the National Heart Lung and Blood Institute website at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm**

---

**References**

Rx for Prevention is published 10 times a year by the Los Angeles County Department of Public Health. If you would like to receive this newsletter by e-mail, go to www.publichealth.lacounty.gov and subscribe to the ListServ for Rx for Prevention.

Upcoming Trainings

Immunization Training Resources for Clinicians
The Los Angeles County Department of Public Health Immunization Program, the California Department of Public Health, the CDC and other entities offer a variety of web-based and in-person immunization training programs for clinicians and staff. Some programs offer CMEs. Visit www.publichealth.lacounty.gov/ip/trainconf.htm.

Immunization Skills Training for Medical Assistants
The Immunization Skills Institute is a 4-hour course that trains medical assistants on safe, effective, and caring immunization skills. Visit www.publichealth.lacounty.gov/ip or call (213) 351-7800.

LOS ANGELES COUNTY BOARD OF SUPERVISORS
Gloria Molina, First District
Mark Ridley-Thomas, Second District
Zev Yaroslavsky, Third District
Don Knabe, Fourth District
Michael D. Antonovich, Fifth District

DEPARTMENT OF PUBLIC HEALTH
Jonathan E. Fielding, MD, MPH
Director and Health Officer
Jonathan Freedman
Chief Deputy, Public Health
Jeffrey D. Gunzenhauser, MD, MPH
Medical Director of Public Health
Steven Teutsch, MD, MPH
Chief Science Officer

EDITORS IN CHIEF
Jeffrey D. Gunzenhauser, MD, MPH
jgunzenhauser@ph.lacounty.gov
Steven Teutsch, MD, MPH
steutsch@ph.lacounty.gov

MEDICAL COMMUNITY ADVISER
Thomas Horowitz, DO

EDITORIAL BOARD
Melanie Barr, RN, MSN
Emily Beeler, DVM, MPH
Trista Bingham, MPH, PhD
James DeCarli, MPH, MPA, CHES
Kevin Donovan, MPH
Julia Heinzerling, MPH
Susan Lesser, MPH
Anna Long, PhD, MPH
David Meyer, MPH
Sadina Reynaldo, PhD
Carrie Tayour, MPH

Summer Nagano, Managing Editor
Alan Albert & Kathleen Pittman, Graphic Designers
Maria Ojeda, Administration

Comments or Suggestions? If so, or if you would like to suggest a topic for a future issue, e-mail Dr. Jeffrey Gunzenhauser, co-editor, at jgunzenhauser@ph.lacounty.gov.

Index of Disease Reporting Forms

All case reporting forms from the LA County Department of Public Health are available by telephone or Internet.

Reportable Diseases & Conditions
Confidential Morbidity Report
Morbidity Unit (888) 397-3993
Acute Communicable Disease Control (213) 240-7941

Sexually Transmitted Disease
Confidential Morbidity Report (213) 744-3070
www.publichealth.lacounty.gov/std/providers.htm (web page)
www.publichealth.lacounty.gov/std/docs/STD_CMR.pdf (form)

Adult HIV/AIDS Case Report Form
For patients over 13 years of age at time of diagnosis
HIV Epidemiology Program (213) 351-8196
www.publichealth.lacounty.gov/HIV/hivreporting.htm

Pediatric HIV/AIDS Case Report Form
For patients less than 13 years of age at time of diagnosis
Pediatric AIDS Surveillance Program (213) 351-8153
Must first call program before reporting www.publichealth.lacounty.gov/HIV/hivreporting.htm

Tuberculosis Suspects & Cases
Confidential Morbidity Report
Tuberculosis Control (213) 744-6160
www.publichealth.lacounty.gov/tb/forms/cmr.pdf

Lead Reporting
No reporting form. Reports are taken over the phone.
Lead Program (323) 869-7195

Animal Bite Report Form
Veterinary Public Health (877) 747-2243
www.publichealth.lacounty.gov/vet/biteintro.htm

Animal Diseases and Syndrome Report Form
Veterinary Public Health (877) 747-2243
www.publichealth.lacounty.gov/vet/disintro.htm

Use of trade names and commercial sources in Rx for Prevention is for identification only and does not imply endorsement by the Los Angeles County Department of Public Health (LACDPH). References to non-LACDPH sites on the Internet are provided as a service to Rx for Prevention readers and do not constitute or imply endorsement of these organizations or their programs by LACDPH. The Los Angeles County Department of Public Health is not responsible for the content of these sites. URL addresses listed in Rx for Prevention were current as of the date of publication.